Clinical Scorecard: A Pharmacologic Off-Switch for Split CARs

At a Glance

Key Highlights

• Venetoclax induces near-total receptor disassembly in DROP-CAR T cells.
• DROP-CAR T cells show reduced cytotoxicity and interferon-γ production upon venetoclax treatment.
• The system employs human protein components and a clinically approved drug for CAR-T cell regulation.

Guideline-Based Recommendations

Diagnosis

• Evaluate tumor expression of prostate-specific membrane antigen or epithelial cell adhesion molecule.

Management

• Consider DROP-CAR T cell therapy with venetoclax for reversible control of T cell activation.

Monitoring & Follow-up

• Monitor receptor disassembly and cytotoxic function in DROP-CAR T cells post-treatment.

Risks

• Potential reduction in immune synapse formation and altered T cell functionality.

Patient & Prescribing Data

Patients with tumors expressing specific antigens suitable for DROP-CAR T cell therapy.

Venetoclax can effectively regulate CAR-T cell activity without immunosuppression.

Clinical Best Practices

• Utilize venetoclax for precise control of CAR-T cell activation in clinical settings.
• Conduct in vitro assessments of DROP-CAR T cell functionality before clinical application.

References

• Nature Chemical Biology